Journal of Histochemistry and Cytochemistry, Vol. 47, 777-786, June 1999, Copyright © 1999, The Histochemical Society, Inc.


ARTICLE

Hakata Antigen, a New Member of the Ficolin/Opsonin p35 Family, Is a Novel Human Lectin Secreted into Bronchus/Alveolus and Bile

Mina Akaiwaa, Yoshiaki Yaea, Rie Sugimotoa, Satoshi O. Suzukib, Toru Iwakib, Kenji Izuharaa, and Naotaka Hamasakia
a Department of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan
b Department of Neuropathology, Neurological Institute, Faculty of Medicine, Kyushu University, Fukuoka, Japan

Correspondence to: Naotaka Hamasaki, Dept. of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, Kyushu Univ., 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.


  Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Hakata antigen was first reported as a serum protein that reacted with an autoantibody from patients with systemic lupus erythematosus. Recently, it has been found that Hakata antigen is a new member of the ficolin/opsonin p35 family, which is a distinct lectin family, on the basis of homology of structures and the common characteristic of possessing lectin activity. In this study we analyzed the tissue distribution of Hakata antigen. Hakata antigen mRNA and protein were generated in the lung and liver. In the lung, Hakata antigen was produced by both ciliated bronchial epithelial cells and Type II alveolar epithelial cells and was secreted into the bronchus and alveolus. In the liver, Hakata antigen was produced by bile duct epithelial cells and hepatocytes and was also secreted into the bile duct. These results demonstrate that Hakata antigen is a unique lectin protein that exists not only in serum but also in bronchus/alveolus and bile, and indicate that Hakata antigen plays a role in bronchus/alveolus and bile under physiological conditions. (J Histochem Cytochem 47:777–785, 1999)

Key Words: Hakata antigen, lectin, ficolin, opsonin p35, bronchus, alveolus, bile


  Introduction
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Hakata antigen was first reported by Inaba and Okochi 1978 as a serum protein that reacted with an autoantibody from patients with systemic lupus erythematosus (SLE). Since then, it has been demonstrated that Hakata antigen is a novel thermolabile ß2-macroglycoprotein that exists as a monomer of 35 kD in reducing conditions and as a huge homopolymer of 650 kD in serum or in nonreducing conditions (Yae et al. 1991 ). All sera from 10,050 healthy Japanese donors, 99.99% of 751,352 Japanese outpatients, and 99.98% of 41,430 Swedish outpatients contained Hakata antigen, showing that Hakata antigen is a normal serum constituent (Inaba et al. 1990 ). The range of Hakata antigen in serum was 7–23 µg/ml (Yae et al. 1991 ).

We have recently identified the cDNA encoding Hakata antigen, revealing that Hakata antigen consists of a collagen-like domain in the middle section and a fibrinogen-like domain in the C terminus, both of which are homologous to two lectin activity-possessing proteins, human ficolin-1 and opsonin p35 (Sugimoto et al. 1998 ). Homologies between Hakata antigen and either human ficolin-1 or opsonin P35 were both 48% overall, higher in the collagen-like domain (48%, 54%) and in the fibrinogen-like domain (52%, 53%), respectively (Sugimoto et al. 1998 ). We have further demonstrated that purified Hakata antigen sustains lectin activity, showing affinity with GalNac, GlcNac, and D-FUCOSE AS MONO/OLIGOSACCHARIDE, AND LPSS FROM Salmonella typhimurium and S. minnesota (Sugimoto et al. 1998 ). These three molecules apparently form a distinct human lectin family. However, the physiological roles of these related molecules have remained unresolved. To date, porcine and mouse homologues of human ficolin-1 and opsonin p35 have been identified, whereas that of Hakata antigen has not been found (Ichijo et al. 1991 , Ichijo et al. 1993 ; Fujimori et al. 1998 ). Most lectin proteins, including all members of this family, exist in serum and are believed to exert their biological activities in serum (Gabius 1997 ). Very few lectin proteins show a different distribution except for surfactant proteins (SPs)-A–D, which are secreted into bronchus/alveolus (Hawgood and Shiffer 1991 ; Wright and Dobbs 1991 ).

Our present analysis of the tissue distribution of Hakata antigen reveals that it is produced by ciliated bronchial epithelial cells and Type II alveolar epithelial cells in the lung and by bile duct epithelial cells and hepatocytes in the liver, which are secreted into bronchus/alveolus and bile duct, respectively.


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Northern Blotting Analysis
A membrane filter blotted with 2 µg of poly(A)+ mRNA from human tissues (Clontech Labs; Palo Alto, CA) was hybridized with 32P-labeled Hakata antigen cDNA fragment (nucleotides 448–864) overnight at 42C in a solution containing 50% formamide, 5 x Denhardt's solution, 5 x SSPE, 0.5% sodium dodecyl sulfate (SDS), and 200 µg/ml salmon sperm DNA. After two extensive washings at room temperature (RT) for 10 min in a 0.1 x standard saline citrate (SSC)/0.1% SDS solution, the filter was exposed to an autoradiographic imaging system and the image was then read using a bioimaging analyzing system (BAS 1000; Fuji Photo Film, Minamiashikaga, Japan).

Preparation of Polyclonal and Monoclonal Antibodies Against Hakata Antigen
A polyclonal antibody against Hakata antigen was produced as described previously (Sugimoto et al. 1998 ). A monoclonal antibody against Hakata antigen was produced using Hakata antigen denatured by pyridylethylation as antigen (Cavins and Friedman 1970 ). Each 200 µg of denatured Hakata antigen was injected along with complete Freund's adjuvant (Difco Laboratories; Detroit, MI) into Balb/c mice. After 4 weeks the mice were boosted with 200 µg of the antigen without adjuvant, and 3 days later spleens were removed to fuse with P3U1 myeloma cells. Hybridoma cells were screened by using an ELISA with Hakata antigen. One of the positive clones was designated Pr19. Antibodies were then collected from ascites of mice bearing the Pr19 hybridoma cells. Pr19 belonged to the IgG1 isotype.

Western Blotting Analysis
Fresh human lung and liver tissues were taken after informed consent from donors undergoing surgery, and the tissues were immediately frozen. Each frozen tissue was homogenized with 50 mM Tris-HCl (pH 8.0) solution containing 8 M urea, 4% SDS, and 5 mM EDTA, and the supernatant was collected after centrifugation. Hakata antigen in serum was purified according to the method used by Yae et al. 1991 . Bronchoalveolar lavage (BAL) fluids from inpatients were provided by the Department of Pathology, Kyushu University Hospital, and were used after removal of cells. Bile samples from inpatients, collected by percutaneous transhepatic cholangio drainage tubes, were provided by the First Department of Surgery, Kyushu University Hospital.

Total homogenates of the human lung and liver tissues, purified Hakata antigen, BAL fluids, and bile were applied to SDS-PAGE and transferred electrophoretically to PVDF membranes (Millipore; Bedford, MA). The membranes were probed with either a polyclonal or a monoclonal antibody against Hakata antigen and were visualized by enhanced chemiluminescence (Tropix; Bedford, MA).

Immunohistochemical Analysis
Autopsy specimens of normal human lung and liver were fixed with 10% formalin solution for about 2 weeks and then embedded in paraffin. The sections were pretreated with 0.1% trypsin for 30 min at 37C and then probed with Pr19 by the biotin–streptavidin method as described (Hitotsumatsu et al. 1997 ). Specificity of the signal was confirmed by the observations that the signal was not elicited by treatment without the primary antibody and that adding an excess amount of pyridylethylated, but not native, Hakata antigen diminished the signal. Anti-Sp-A antibody and anti-CC10 antibody were kindly provided by Dr. S. Hashimoto (Kyushu University).


  Results
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Expression of Hakata Antigen mRNA
To determine which tissues express Hakata antigen, we first performed Northern blotting using a complementary oligonucleotide to Hakata antigen (nucleic acids 448–864 from the translation starting site) as a probe. This oligonucleotide hybridized mRNAs derived from the lung and liver (Figure 1). No band was detected in mRNAs of spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood leukocytes, heart, brain, placenta, skeletal muscle, or kidney (Figure 1; data not shown). The sizes of the bands were about 1.3 KB. BANDS CORRESPONDING TO GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE WERE DETECTED IN ALL TISSUES (NOT SHOWN). THIS RESULT INDICATES THAT THE LUNG AND LIVER ARE THE PRINCIPAL ORGANS THAT PRODUCE HAKATA ANTIGEN. WE THEREFORE FOCUSED ON THE LUNG AND LIVER TO ANALYZE THE EXPRESSION OF HAKATA ANTIGEN PROTEIN.



View larger version (57K):
[in this window]
[in a new window]
 
Figure 1. Northern blotting of Hakata antigen. A membrane filter containing mRNA from human tissues was hybridized with 32P-labeled Hakata antigen cDNA fragment (nucleotides 448–864). mRNAs are derived from 1, heart; 2, brain; 3, placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney. Size markers are indicated at left. Arrow indicates the band of Hakata antigen.

Western Blotting of Hakata Antigen in Lung and Liver
To confirm that the lung and liver express Hakata antigen protein as well as mRNA, we next carried out Western blotting of Hakata antigen using total homogenates of lung and liver. Using the polyclonal antibody against Hakata antigen, the homogenates of both lung and liver gave rise to sharp bands whose sizes were identical to that of Hakata antigen purified from serum, although some bands of higher molecular weight were also detected in the case of the liver (Figure 2). It is unlikely that these bands are polymeric forms because Hakata antigen exists as a monomer under reducing conditions. These results suggest that the lung and liver are rich in Hakata antigen protein, whose molecular size is almost the same as that in serum.



View larger version (36K):
[in this window]
[in a new window]
 
Figure 2. Western blotting of Hakata antigen in lung and liver. Ten ng (A, Lane 1) and 30 ng (B, Lane 1) of purified Hakata antigen, and supernatant of either lung tissue (A, Lane 2) and liver tissue (B, Lane 2) were probed with a polyclonal antibody against Hakata antigen. Molecular size markers are indicated at left. Arrow indicates the band of Hakata antigen (35 kD).

Generation of a Monoclonal Antibody Against Hakata Antigen (Pr19)
We have previously shown that Hakata antigen exists as a polymer consisting of disulfide bonds in serum and that polyclonal rabbit antiserum against Hakata antigen recognizes both monomeric and polymeric Hakata antigens (Yae et al. 1991 ). Because the polyclonal antibody caused nonspecific background staining in immunohistochemistry (not shown), we attempted to generate a monoclonal antibody against Hakata antigen for immunohistochemistry. One hybridoma clone (Pr19) produced an antibody that specifically recognized monomeric Hakata antigen but not polymeric Hakata antigen (Figure 3). We applied this antibody in the following immunohistochemical analyses.



View larger version (31K):
[in this window]
[in a new window]
 
Figure 3. Western blotting of Hakata antigen by Pr19. One µg of purified Hakata antigen was probed with a monoclonal antibody against Hakata antigen (Pr19) in either nonreducing (Lane 1) or reduc-ing (Lane 2) conditions. Molecular size markers are indicated at left. Arrow indicates the band of monomeric Hakata antigen (35 kD).

Expression of Hakata Antigen in Lung
To localize Hakata antigen protein expressed in human lung, we carried out immunohistochemical analyses using Pr19. In the alveolar region, Type II alveolar epithelial cells, characterized by their round shape and plump cytoplasm, showed strong cytoplasmic staining with Pr19 (Figure 4A and Figure 4B), whereas Type I alveolar epithelial cells, alveolar macrophages, and endothelial cells were not stained. To confirm that Type II alveolar epithelial cells were stained by Pr19, we stained two sequential sections with either Pr19 (Figure 4B) or anti-SP-A antibody (Figure 4C) because SP-A is known to be secreted from Type II alveolar epithelial cells (Hawgood and Shiffer 1991 ; Wright and Dobbs 1991 ). In these sections, both antibodies recognized Type II alveolar epithelial cells. In the bronchus and bronchioles, ciliated columnar epithelial cells were mainly stained by Pr19 (Figure 4A and Figure 4D). Reserve cells of the epithelium located in the basal membrane were also strongly stained. These reaction products showed fine granular deposits in their cytoplasm; however, goblet cells were negative for Pr19 staining. To confirm that ciliated epithelial cells were mainly stained by Pr19, we stained sequential sections with either Pr19 (Figure 4E) or anti-SP-A antibody (Figure 4 F) or with anti-CC10 antibody (Figure 4G), the latter two of which are known to recognize Clara cells (Xu et al. 1998 ). Consequently, Pr19 gave rise to positive staining mainly in ciliated epithelial cells, whereas anti-SP-A antibody and anti-CC10 antibody did so in nonciliated epithelial cells (Clara cells). The staining pattern of Pr19 was the same in lung tissue derived from six different individuals (not shown). The results suggest that the monomeric Hakata antigen recognized by Pr19 was produced specifically by Type II alveolar epithelial cells and ciliated bronchial epithelial cells in human lung.



View larger version (100K):
[in this window]
[in a new window]
 
Figure 4. Immunoperoxidase staining of human lung probed with Pr19. (A) Bronchiolus and alveoli. Bar = 200 µm. (B) Higher magnification of A, showing positive reaction in the Type II alveolar epithelial cells. (B,C) Sequential alveoli showing Type II alveolar epithelial cells positively stained with Pr19 (B) and anti-SP-A antibody (C). Bars = 50 µm. (D) Higher magnification of A, showing positive reaction in the bronchial epithelial cells. Goblet cells (the arrow) were negative. Bar = 25 µm. (E–G) Sequential bronchioli, showing that Pr19 stained ciliated epithelial cells but not Clara cells (D), whereas anti-SP-A antibody (F) and anti-CC10 antibody (G) stained Clara cells but not ciliated epithelial cells. Bars = 10 µm.

To clarify whether Hakata antigen is secreted into bronchus/alveolus, we subjected BAL fluids to Western blotting of Hakata antigen. In nonreducing conditions, a polymeric Hakata antigen with the same mobility as that in serum was detected in all BAL fluids from eight donors (Figure 5A), whereas in reducing conditions these polymeric Hakata antigens in BAL fluid dissociated to monomeric ones (35 kD; Figure 5B). These results demonstrated that the Hakata antigen generated in bronchial epithelial cells and Type II alveolar epithelial cells in human lung is secreted as a polymer into bronchus/alveolus.



View larger version (39K):
[in this window]
[in a new window]
 
Figure 5. Western blotting of Hakata antigen in BAL fluid. Thirty ng of purified Hakata antigen (Lane 1, A,B) and BAL fluids from inpatients (A,B, Lanes 2–8) were blotted with a polyclonal antibody against Hakata antigen in either nonreducing (A) or reducing (B) conditions. The patients used in this experiment were diagnosed with fungal pneumonia (Lane 2), lung cancer (Lanes 3 and 8), pulmonary tuberculosis (Lane 4), idiopathic interstitial pneumonitis (Lane 5), sarcoidosis (Lane 6), and interstitial pneumonitis (Lane 7). Molecular size markers are indicated at left.

Expression of Hakata Antigen in Liver
In liver, hepatocytes showed diffuse and weak staining of the cytoplasm by Pr19 (Figure 6A and Figure 6B), and bile duct epithelial cells were strongly stained (Figure 6A and Figure 6C). Kupffer cells, sinusoidal capillaries around hepatocytes, and Glisson's sheath around bile ducts were not stained. These results demonstrated that monomeric Hakata antigen protein is produced in both hepatocytes and bile duct epithelial cells, but to a much greater extent in the latter. The staining pattern was the same in liver tissue derived from seven different individuals (not shown).



View larger version (94K):
[in this window]
[in a new window]
 
Figure 6. Immunoperoxidase staining of human liver probed with Pr19. (A) Liver. Bar = 100 µm. (B) Higher magnification of A, showing weak immunoreaction in hepatocytes. Bar = 50 µm. (C) Higher magnification of A, showing that bile duct epithelial cells are immunopositive. Bar = 50 µm.

To clarify whether Hakata antigen is secreted into bile ducts, we subjected bile samples to Western blotting. In nonreducing conditions, polymeric Hakata antigen protein, which has the same mobility as that in serum, was detected in all samples, whereas in reducing conditions only monomeric Hakata antigen was detected in bile as in BAL fluid (Figure 7). Although the intensity of the bands was very weak in Lanes 3 and 7, longer exposure of the film gave rise to definite bands. Therefore, Hakata antigen, which is formed in bile duct epithelial cells, is secreted as a polymer into bile ducts.



View larger version (41K):
[in this window]
[in a new window]
 
Figure 7. Western blotting of Hakata antigen in bile. Twenty-five ng of purified Hakata antigen (Lane 1, A,B) and bile of inpatients (A,B, Lanes 2–7) were probed with a polyclonal antibody against Hakata antigen in either nonreducing (A) or reducing (B) conditions. The patients used in this experiment were diagnosed with cholangiocarcinoma (Lane 2), cholelithiasis (Lanes 3, 5–7), and primary sclerotic cholangitis (Lane 4). Molecular size markers are indicated at left.


  Discussion
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

It has recently been shown that Hakata antigen is a new member of the ficolin/opsonin p35 family by cloning of its cDNA and by functional analyses (Sugimoto et al. 1998 ). Hakata antigen shows overall homologies of 48% with both human ficolin-1 and opsonin p35, higher in the collagen-like domain (48%, 54%) and in the fibrinogen-like domain (52%, 53%), respectively (Sugimoto et al. 1998 ). Although animal lectins are categorized into several groups (Gabius 1997 ), it is believed that the ficolin/opsonin p35 family is distinct from the others. However, the physiological roles of these members await elucidation. In this study we examined the tissue distribution of Hakata antigen to obtain clues about its physiological role. Taking together the results of Northern blotting, Western blotting, and immunohistochemical analyses of lung and liver, we have concluded that Hakata antigen is a novel lectin protein secreted into bronchus/alveolus and bile duct, extending previous reports that it is a novel serum protein (Yae et al. 1991 ; Sugimoto et al. 1998 ). These results indicate that Hakata antigen may play a role not only in serum but also in bronchus/alveolus and bile duct under physiological conditions. Among the other members of the ficolin/opsonin p35 family, it has been shown that mRNA of human ficolin-1 is expressed in peripheral blood leukocytes, spleen, lung, placenta, and thymus (Harumiya et al. 1996 ; Lu et al. 1996 ), whereas that of opsonin p35 is expressed in liver, lung, and placenta (Matsushita et al. 1996 ), although it is not known which cells in these organs produce these molecules. The finding that mRNAs of both molecules are expressed in either lung or liver, like Hakata antigen, raises the possibility that all members of the ficolin/opsonin p35 family are secreted into either bronchus/alveolus or bile and may play a similar role in these areas. On the other hand, the notion that peripheral blood leukocytes are a major source of human ficolin-1 (Harumiya et al. 1996 ; Lu et al. 1996 ), whereas mRNA of Hakata antigen was not detected in peripheral blood leukocytes, suggests that these three molecules play distinct roles in different areas of the body.

We have demonstrated in this study that Hakata antigen as well as SPs was secreted into bronchus and alveolus. SP-A and SP-D are known to be water-soluble and to sustain lectin activity (Kuroki and Voelker 1994 ). Although these two SPs belong to the C-type lectin superfamily, whereas Hakata antigen does not, all of these molecules share common characteristics: (a) they are secreted by Type II alveolar epithelial cells; (b) collagen-like domains exist in the middle of the molecules; (c) these proteins form polymers consisting of octodecamers (SP-A, Hakata antigen) or a dodecamer (SP-D); and (d) these proteins can bind to carbohydrates (Kuroki and Voelker 1994 ). The difference between Hakata antigen and SP-A is that, in the bronchus and bronchioles, Hakata antigen is mainly produced by ciliated epithelial cells, whereas SP-A is produced by Clara cells. It has been shown that SP-A and SP-D play two important roles in bronchus and alveolus. One is the pulmonary surfactant system; these SPs bind to phospholipid to generate the surfactant monolayer, lowering surface tension at the air–liquid interface (Hawgood and Shiffer 1991 ; Weaver and Whitsett 1991 ; Wright and Dobbs 1991 ). The other is that these molecules modulate host defense functions in the lung by stimulating phagocytosis and chemotaxis of macrophages and by binding to a variety of microorganisms (Tenner et al. 1989 ; Kuan et al. 1992 ; van Iwaarden et al. 1991 , van Iwaarden et al. 1992 ; Zimmerman et al. 1992 ; Wright and Youmans 1993 ). On the basis of analogies in the distribution, structure, and function of these SPs and Hakata antigen, it is assumed that Hakata antigen plays roles similar to these SPs. Further studies aimed at this point are needed.

In previous studies, it has been verified that Hakata antigen is a novel serum protein with a range of 7–23 µg/ml (Yae et al. 1991 ). This value means that Hakata antigen is a relatively abundant protein, whose concentration is equivalent to those of some complement proteins, such as C1q, C2, C5-9 (20–80 µg/ml). The serum concentration of human ficolin-1 has been reported to be at the same level as that of Hakata antigen (1–7 µg/ml, average 4.13 µg/ml; Le et al. 1998 ). It has been unclear which tissue is the main source of Hakata antigen in serum in the body. However, our present findings suggest that Hakata antigen in serum is produced in hepatocytes. This notion is compatible with the finding that the serum level of Hakata antigen declines in patients with liver cirrhosis (Fukutomi et al. 1996 ).

Bile duct epithelial cells are known to modify hepatic bile by both secretory and absorptive processes, producing as much as 40% of the daily output of bile (Boyer 1996 ). We have demonstrated here that Hakata antigen was produced by bile duct epithelial cells and secreted into the bile duct. To our knowledge, no lectin protein, other than Hakata antigen, has been shown to exist in bile. Its function remains unclear. It is well known that bile contains various kinds of glycoproteins that bind to lectins. These glycoproteins include mucin glycoproteins, which are the most abundant, and nonmucin glycoproteins, such as aminopeptidase N, {alpha}2-macroglobulin, hemopexin, immunoglobulin heavy chains, and the ß-chain of haptoglobulin (Klinkspoor et al. 1994 ; Lipsett et al. 1994 ; Offner et al. 1994 ; van Wijland et al. 1994 ; Busch et al. 1995 ). These glycoproteins play important roles in protection against the detergent action of bile salts under physiological conditions, and in cholesterol crystallization under pathological conditions (Klinkspoor et al. 1994 ; Lipsett et al. 1994 ; Offner et al. 1994 ; van Wijland et al. 1994 ; Busch et al. 1995 ). Likewise, Hakata antigen may associate with these glycoproteins in bile and may affect the activities of these glycoproteins. Although the present limited analyses of inpatient bile did not show any significant difference in the amount of Hakata antigen contained (Figure 7), further studies focused on the association between Ha-kata antigen and these glycoproteins under either phys-iological or pathological conditions would be useful.


  Acknowledgments

Supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.

Dr Yae passed away in August of 1996. This work is dedicated to Dr Yae's collaborative efforts in scientific research in a career spanning nearly a quarter of a century.

We thank Ms K. Hatanaka for skillful help and Dr S. Hashimoto for providing antibodies against SP-A and CC10. We also thank Dr Dovie R. Wylie for critical review of this manuscript.

Received for publication August 26, 1998; accepted January 12, 1999.


  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Boyer JL (1996) Bile duct epithelium: frontiers in transport physiology. Am J Physiol 270:G1-5[Abstract/Free Full Text]

Busch N, Lammert F, Marschall HU, Matern S (1995) A new subgroup of lectin-bound biliary proteins binds to cholesterol crystals, modifies crystal morphology, and inhibits cholesterol crystallization. J Clin Invest 96:3009-3015[Medline]

Cavins JF, Friedman M (1970) An internal standard for amino acid analyses: s-ß-(4-pyridylethyl)-L-cysteine. Anal Biochem 35:489-493[Medline]

Fujimori Y, Harumiya S, Fukumoto Y, Miura Y, Yagasaki K, Tachikawa H, Fujimoto D (1998) Molecular cloning and characterization of mouse ficolin-A. Biochem Biophys Res Commun 244:798-800

Fukutomi T, Ando B, Sakamoto S, Sakai H, Nawata H (1996) Thermolabile ß-2 macroglycoprotein (Hakata antigen) in liver disease: biochemical and immunohistochemical study. Clin Chim Acta 255:93-106[Medline]

Gabius H (1997) Animal lectins. Eur J Biochem 243:543-576[Abstract]

Harumiya S, Takeda K, Sugiura T, Fukumoto Y, Tachikawa H, Miyazono K, Fujimoto D, Ichijo H (1996) Characterization of ficolins as novel elastin-binding proteins and molecular cloning of human ficolin-1. J Biochem (Tokyo) 120:745-751[Abstract]

Hawgood S, Shiffer K (1991) Structures and properties of the surfactant-associated proteins. Annu Rev Physiol 53:375-394[Medline]

Hitotsumatsu T, Iwaki T, Kitamoto T, Mizoguchi M, Suzuki S, Hamada Y, Fukui M, Tateishi J (1997) Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol (Berl) 93:225-232[Medline]

Ichijo H, Hellman U, Wernstedt C, Gonez LJ (1993) Molecular cloning and characterization of ficolin, a multimeric protein with fibrinogen- and collagen-like domains. J Biol Chem 268:14505-14513[Abstract/Free Full Text]

Ichijo H, Rönnstrand L, Miyagawa K, Ohashi H, Heldin C, Miyazono K (1991) Purification of transforming growth factor-ß1 binding proteins from porcine uterus membranes. J Biol Chem 266:22459-22464[Abstract/Free Full Text]

Inaba S, Okochi K (1978) On a new precipitating antibody against normal human serum found in two patients with SLE. Igaku No Ayumi 107:690-691. (in Japanese)

Inaba S, Okochi K, Yae Y (1990) Serological studies of an SLE-associated antigen-antibody system discovered as a precipitation reaction in agarose gel: the HAKATA antigen-antibody system. Fukuoka Acta Medica 81:284-291

Klinkspoor JH, van Wijland MJ, Koeleman CA, van Dijk W, Tytgat GN, Groen AK (1994) Heterogeneity of human biliary mucin: functional implications. Clin Sci 86:75-82[Medline]

Kuan SF, Rust K, Crouch E (1992) Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest 90:97-106[Medline]

Kuroki Y, Voelker DR (1994) Pulmonary surfactant proteins. J Biol Chem 269:25943-25946[Free Full Text]

Le Y, Lee SH, Kon OL, Lu J (1998) Human L-ficolin: plasma levels, sugar specificity, and assignment of its lectin activity to the fibrinogen-like (FBG) domain. FEBS Lett 425:367-370[Medline]

Lipsett PA, Hildreth J, Kaufman HS, Lillemoe KD, Pitt HA (1994) Human gallstones contain pronucleating nonmucin glycoproteins that are immunoglobulins. Ann Surg 219:25-33[Medline]

Lu J, Tay PN, Kon OL, Reid KBM (1996) Human ficolin: cDNA cloning, demonstration of peripheral blood leucocytes as the major site of synthesis and assignment of the gene to chromosome 9. Biochem J 313:473-478[Medline]

Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Mizouchi T (1996) A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J Biol Chem 271:2448-2454[Abstract/Free Full Text]

Offner GD, Gong D, Afdhal NH (1994) Identification of a 130-kilodalton human biliary concanavalin A binding protein as aminopeptidase N. Gastroenterology 106:755-762[Medline]

Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N (1998) Cloning and characterization of Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem 273:20721-20727[Abstract/Free Full Text]

Tenner AJ, Robinson SL, Borchelt J, Wright JR (1989) Human pulmonary surfactant protein (SP-A), a protein structurally homologous to C1q, can enhance FcR- and CR1-mediated phagocytosis. J Biol Chem 264:13923-13928[Abstract/Free Full Text]

van Iwaarden JF, Shimizu H, van Golde PH, Voelker DR, van Golde LM (1992) Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages. Biochem J 286:5-8[Medline]

van Iwaarden JF, van Strijp JA, Ebskamp MJ, Welmers AC, van Golde LM (1991) Surfactant protein A is opsonin in phagocytosis of Herpes simplex virus type 1 by rat alveolar macrophages. Am J Physiol 261:L204-209[Abstract/Free Full Text]

van Wijland MJ, Klinkspoor JH, de Wit LT, Oude Elferink RP, Tytgat GN, Groen AK (1994) Heterogeneity of human biliary mucin: functional implications. Clin Sci 86:67-74[Medline]

Weaver TE, Whitsett JA (1991) Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem J 273:249-264[Medline]

Wright JR, Dobbs LG (1991) Regulation of pulmonary surfactant secretion and clearance. Annu Rev Physiol 53:395-414[Medline]

Wright JR, Youmans DC (1993) Pulmonary surfactant protein A stimulates chemotaxis of alveolar macrophage. Am J Physiol 264:L338-344[Abstract/Free Full Text]

Xu P, Hashimoto S, Miyazaki H, Asabe K, Shiraishi S, Sueishi K (1998) Morphometric analysis of the immunohistochemical expression of Clara cell 10-kDa protein and surfactant apoproteins A and B in the developing bronchi and bronchioles of human fetuses and neonates. Virchows Arch 432:17-25[Medline]

Yae Y, Inaba S, Sato H, Okochi K, Tokunaga F, Iwanaga S (1991) Isolation and characterization of a thermolabile ß-2 macroglycoprotein (`thermolabile substance' or `Hakata antigen') detected by precipitating (auto) antibody in sera of patients with systemic lupus erythematosus. Biochim Biophys Acta 1078:369-376[Medline]

Zimmerman PE, Voelker DR, McCormack FX, Paulsrud JR, Martin WJ, II (1992) 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A. J Clin Invest 89:143-149[Medline]